UA82503C2 - Жидкая композиция белка, который связывает фактор некроза опухолей - Google Patents
Жидкая композиция белка, который связывает фактор некроза опухолей Download PDFInfo
- Publication number
- UA82503C2 UA82503C2 UAA200508323A UA2005008323A UA82503C2 UA 82503 C2 UA82503 C2 UA 82503C2 UA A200508323 A UAA200508323 A UA A200508323A UA 2005008323 A UA2005008323 A UA 2005008323A UA 82503 C2 UA82503 C2 UA 82503C2
- Authority
- UA
- Ukraine
- Prior art keywords
- composition according
- tumor necrosis
- necrosis factor
- tme
- buffer
- Prior art date
Links
- 102000019506 tumor necrosis factor binding proteins Human genes 0.000 title description 2
- 108091016215 tumor necrosis factor binding proteins Proteins 0.000 title description 2
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000000872 buffer Substances 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 108091008324 binding proteins Proteins 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 239000007951 isotonicity adjuster Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 229940100630 metacresol Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 32
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 21
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000023732 binding proteins Human genes 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012907 medicinal substance Substances 0.000 description 7
- 229950010444 onercept Drugs 0.000 description 7
- 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Bromobutyl Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101710187780 Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920005557 bromobutyl Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000011253 protective coating Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 2
- 239000011123 type I (borosilicate glass) Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 101150072179 ATP1 gene Proteins 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 1
- 101710178436 Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 1
- 101710187885 Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101710187887 Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение касается стойкой фармацевтически приемлемой водной композиции TNF-связующего белка, который содержит ТВР-1 как TNF-связующий белок, буфер и изотонический агент, причем буфером является фосфатный буфер, который удерживает уровень рН в пределах от 6 до 7, а изотоническим агентом является хлорид натрия или маннит.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100505 | 2003-02-28 | ||
| PCT/EP2004/050118 WO2004075918A1 (en) | 2003-02-28 | 2004-02-11 | Liquid formulations of tumor necrosis factor-binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82503C2 true UA82503C2 (ru) | 2008-04-25 |
Family
ID=32921619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200508323A UA82503C2 (ru) | 2003-02-28 | 2004-11-02 | Жидкая композиция белка, который связывает фактор некроза опухолей |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8937045B2 (ru) |
| EP (1) | EP1603596B1 (ru) |
| JP (1) | JP4980048B2 (ru) |
| KR (1) | KR20050105486A (ru) |
| CN (1) | CN100563712C (ru) |
| AR (1) | AR043418A1 (ru) |
| AT (1) | ATE394123T1 (ru) |
| BR (1) | BRPI0407649A (ru) |
| CA (1) | CA2515539A1 (ru) |
| DE (1) | DE602004013557D1 (ru) |
| EA (1) | EA009079B1 (ru) |
| ES (1) | ES2304602T3 (ru) |
| HR (1) | HRP20050706A2 (ru) |
| IL (1) | IL170414A (ru) |
| MX (1) | MXPA05009135A (ru) |
| NO (1) | NO20054440L (ru) |
| PL (1) | PL213501B1 (ru) |
| RS (1) | RS51041B (ru) |
| UA (1) | UA82503C2 (ru) |
| WO (1) | WO2004075918A1 (ru) |
| ZA (1) | ZA200506504B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| LT2637690T (lt) | 2010-11-11 | 2016-10-25 | Abbvie Biotechnology Ltd | Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos |
| DK2726090T3 (da) | 2011-07-01 | 2020-01-20 | Biogen Ma Inc | Argininfri tnfr: fc-fusionspolypeptidsammensætninger |
| HK1200721A1 (en) | 2011-10-18 | 2015-08-14 | 科荣生生物科学公司 | Etanercept formulations stabilized with xylitol |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CA3078979C (en) * | 2011-10-31 | 2022-10-11 | Genentech, Inc. | Formulation comprising an anti-il13 antibody having extended stability |
| BR112015000229A2 (pt) | 2012-07-09 | 2017-06-27 | Coherus Biosciences Inc | formulações aquosas estáveis de etanercept |
| CN110051823A (zh) | 2012-09-11 | 2019-07-26 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
| WO2014064637A1 (en) | 2012-10-26 | 2014-05-01 | Lupin Limited | Stable pharmaceutical composition of tnfr:fc fusion protein |
| KR101692884B1 (ko) | 2014-06-26 | 2017-01-04 | 마루이시세이야쿠가부시키가이샤 | 안정성을 개선한 로쿠로늄 제제 |
| RU2724900C1 (ru) * | 2019-10-24 | 2020-06-26 | Маруиси Фармасьютикал Ко., Лтд. | Препарат рокурония с улучшенной стабильностью |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0620739A4 (en) * | 1992-09-15 | 1997-01-15 | Immunex Corp | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. |
| CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
| DE69525181T2 (de) * | 1995-07-14 | 2002-08-14 | Applied Research Systems Ars Holding N.V., Curacao | Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie |
| MA24169A1 (fr) | 1996-05-08 | 1997-12-31 | Hoffmann La Roche | Traitement de l'asthme a l'aide de la tnfr-ig |
| AU5696198A (en) * | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| US20030180287A1 (en) * | 2002-02-27 | 2003-09-25 | Immunex Corporation | Polypeptide formulation |
-
2004
- 2004-02-11 EP EP04710041A patent/EP1603596B1/en not_active Expired - Lifetime
- 2004-02-11 HR HR20050706A patent/HRP20050706A2/hr not_active Application Discontinuation
- 2004-02-11 PL PL378290A patent/PL213501B1/pl unknown
- 2004-02-11 RS YUP-2005/0662A patent/RS51041B/sr unknown
- 2004-02-11 CA CA002515539A patent/CA2515539A1/en not_active Abandoned
- 2004-02-11 JP JP2006502021A patent/JP4980048B2/ja not_active Expired - Fee Related
- 2004-02-11 WO PCT/EP2004/050118 patent/WO2004075918A1/en not_active Ceased
- 2004-02-11 CN CNB2004800103089A patent/CN100563712C/zh not_active Expired - Lifetime
- 2004-02-11 AT AT04710041T patent/ATE394123T1/de not_active IP Right Cessation
- 2004-02-11 US US10/547,307 patent/US8937045B2/en not_active Expired - Fee Related
- 2004-02-11 ES ES04710041T patent/ES2304602T3/es not_active Expired - Lifetime
- 2004-02-11 BR BRPI0407649-4A patent/BRPI0407649A/pt not_active IP Right Cessation
- 2004-02-11 EA EA200501230A patent/EA009079B1/ru not_active IP Right Cessation
- 2004-02-11 KR KR1020057015762A patent/KR20050105486A/ko not_active Withdrawn
- 2004-02-11 DE DE602004013557T patent/DE602004013557D1/de not_active Expired - Lifetime
- 2004-02-11 MX MXPA05009135A patent/MXPA05009135A/es active IP Right Grant
- 2004-02-27 AR ARP040100618A patent/AR043418A1/es not_active Application Discontinuation
- 2004-11-02 UA UAA200508323A patent/UA82503C2/ru unknown
-
2005
- 2005-08-15 ZA ZA200506504A patent/ZA200506504B/en unknown
- 2005-08-22 IL IL170414A patent/IL170414A/en active IP Right Grant
- 2005-09-26 NO NO20054440A patent/NO20054440L/no not_active Application Discontinuation
-
2014
- 2014-12-15 US US14/570,244 patent/US9512215B2/en not_active Expired - Fee Related
-
2016
- 2016-09-30 US US15/283,001 patent/US20170020960A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2515539A1 (en) | 2004-09-10 |
| HRP20050706A2 (en) | 2005-12-31 |
| PL378290A1 (pl) | 2006-03-20 |
| EP1603596A1 (en) | 2005-12-14 |
| US20070053906A1 (en) | 2007-03-08 |
| JP4980048B2 (ja) | 2012-07-18 |
| DE602004013557D1 (de) | 2008-06-19 |
| EA200501230A1 (ru) | 2006-04-28 |
| PL213501B1 (pl) | 2013-03-29 |
| WO2004075918A1 (en) | 2004-09-10 |
| ES2304602T3 (es) | 2008-10-16 |
| RS51041B (sr) | 2010-10-31 |
| US20170020960A1 (en) | 2017-01-26 |
| US9512215B2 (en) | 2016-12-06 |
| BRPI0407649A (pt) | 2006-02-21 |
| ATE394123T1 (de) | 2008-05-15 |
| HK1085677A1 (zh) | 2006-09-01 |
| CN100563712C (zh) | 2009-12-02 |
| EP1603596B1 (en) | 2008-05-07 |
| KR20050105486A (ko) | 2005-11-04 |
| JP2006519210A (ja) | 2006-08-24 |
| AR043418A1 (es) | 2005-07-27 |
| MXPA05009135A (es) | 2005-10-20 |
| CN1774266A (zh) | 2006-05-17 |
| IL170414A (en) | 2009-11-18 |
| ZA200506504B (en) | 2006-12-27 |
| NO20054440L (no) | 2005-09-26 |
| RS20050662A (sr) | 2007-11-15 |
| AU2004216483A1 (en) | 2004-09-10 |
| EA009079B1 (ru) | 2007-10-26 |
| US20150098950A1 (en) | 2015-04-09 |
| US8937045B2 (en) | 2015-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102100282B1 (ko) | 항-프로락틴 수용체 항체 제제 | |
| AU2007240732B2 (en) | Buffering agents for biopharmaceutical formulations | |
| AU2007307107B2 (en) | Stable antibody formulations | |
| EP4364724A2 (en) | High concentration vegf receptor fusion protein containing formulations | |
| UA82503C2 (ru) | Жидкая композиция белка, который связывает фактор некроза опухолей | |
| KR20170005864A (ko) | 액체 제약 조성물 | |
| KR102735988B1 (ko) | 치료 항체 제제 | |
| EP3888678A1 (en) | Anti-pd-l1 antibody preparation | |
| CN101795670A (zh) | G-csf的液体制剂 | |
| AU2012200284B2 (en) | Stable Antibody Formulations | |
| JP7548475B1 (ja) | 抗体製剤 | |
| CA3129901C (en) | Therapeutic antibody formulation | |
| WO2024190892A1 (ja) | 抗体製剤 | |
| AU2004216483B2 (en) | Liquid formulations of tumor necrosis factor-binding proteins | |
| CN120754244A (zh) | 一种含抗cd19抗体的药物组合物及其用途 | |
| KR20230026407A (ko) | 액티빈 a 항체 제형 및 이의 사용 방법 | |
| AU2020364480A1 (en) | Stable liquid composition, method for preparing same, and formulation comprising same | |
| WO2014089957A1 (zh) | 一种稳定的白消安注射剂 | |
| HK1085677B (en) | Liquid formulations of tumor necrosis factor-binding proteins |